Celldex Therapeutics, Inc.
222 Cameron Drive
Phillipsburg, NJ. 08865
Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.
Many of our clinical programs seek to leverage the power of the immune system’s response by combining therapeutic approaches to maximize their potential. Key to this strategy is our ability to understand our own asset base while also identifying promising external technologies that will complement it. In 2005, Celldex was spun out of the New Jersey based biopharmaceutical company Medarex (now a subsidiary of the Bristol-Myers Squibb Company) and, in connection with this transaction, Celldex retains the rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform. Since its inception, Celldex has also acquired four companies, folding in three assets, and in-licensed/purchased an additional two assets. With the potential for positive results in ongoing late stage programs, the next stage in Celldex’s development is to become a fully-integrated commercial entity.
News and Press Releases:
Events and Presentations:
250 Royall Street
Canton, MA 02021
Phone: (US) 800-736-3001 / (Int’l) 781-575-2000
See SEC filings
Investor Relations & Corporate Communications
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
|CLDX News: SVB Securities Thinks Celldex’s Stock is Going to Recover||07/03/2022 10:44:22 PM|
|CLDX News: Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022||06/30/2022 06:01:16 PM|
|CLDX News: Current Report Filing (8-k)||06/23/2022 04:04:24 PM|
|CLDX News: H.C. Wainwright Thinks Celldex’s Stock is Going to Recover||06/21/2022 10:05:43 AM|
|CLDX News: Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria||06/21/2022 08:00:00 AM|